All The Claims

1-5. (canceled)
6. A method for treating a mammalian subject with a condition selected from the group consisting of insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis comprising administering to the subject an amount of a biologically active agent, wherein the agent is a compound of the formula:
wherein
n is 1 or 2;
m is 0, 1, 2, 4, or 5;
q is 0 or 1;
t is 0 or 1;
R2 is alkyl having from 1 to 3 carbon atoms;
R3 is hydrogen, halo, alkyl having from 1 to 3 carbon atoms, or alkoxy having from 1 to 3 carbon atoms;
A is phenyl, unsubstituted or substituted by 1 or 2 groups selected from: halo, alkyl having 1 or 2 carbon atoms, perfluoromethyl, alkoxy having 1 or 2 carbon atoms, and perfluoromethoxy; or
cycloalkyl having from 3 to 6 ring carbon atoms wherein the cycloalkyl is unsubstituted or one or two ring carbons are independently mono-substituted by methyl or ethyl; or
a 5 or 6 membered heteroaromatic ring having 1 or 2 ring heteroatoms selected from N, S and O and the heteroaromatic ring is covalently bound to the remainder of the compound of formula I by a ring carbon; and

R1 is hydrogen or alkyl having 1 or 2 carbon atoms;
or when R1 is hydrogen, a pharmaceutically acceptable salt of the compound.
7. The method of claim 6, wherein n is 1; q is 0; t is 0; R3 is hydrogen; and
A is phenyl, unsubstituted or substituted by 1 or 2 groups selected from: halo, alkyl having 1 or 2 carbon atoms, perfluoromethyl, alkoxy having 1 or 2 carbon atoms, and perfluoromethoxy.
8. The method of claim 7, wherein wherein A is 2,6-dimethylphenyl.
9. The method of claim 8, wherein the biologically active agent is selected from the group consisting of:
3-(2,6-Dimethylbenzyloxy)phenylacetic acid;
3-(2,6-Dimethylbenzyloxy)benzoic acid;
Ethyl 3-(2,6-dimethylbenzyloxy)benzoate;
6-3-(2,6-Dimethylbenzyloxy)-phenyl-hexanoic acid;
Ethyl 6-3-(2,6-dimethylbenzyloxy)-phenyl-hexanoate;
5-3-(2,6-Dimethylbenzyloxy)-phenyl-pentanoic acid;
Ethyl 5-3-(2,6-dimethylbenzyloxy)-phenyl-pentanoate;
3-3-(2,6-dimethylbenzyloxy)phenyl-propionic acid; and
Ethyl 3-3-(2,6-dimethylbenzyloxy)phenyl-propanoate.
10. The method of claim 6, wherein the subject is a human.
11. The method of claim 10, wherein the agent is administered orally in an amount from one milligram to four hundred milligrams per day.
12. The method of claim 6, wherein the condition is insulin resistance syndrome or Type II Diabetes.
13. The method of claim 6, wherein the treatment reduces a symptom of diabetes or the chances of developing a symptom of diabetes, wherein the symptom is selected from the group consisting of: atherosclerosis, obesity, hypertension, hyperlipidemia, fatty liver disease, nephropathy, neuropathy, retinopathy, foot ulceration and cataracts, associated with diabetes.
14. A pharmaceutical composition for use in the treatment of a condition selected from the group consisting of insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis, arteriosclerosis and adapted for oral administration, comprising a pharmaceutically acceptable carrier and from one milligram to four hundred milligrams of a biologically active agent, wherein the agent is a compound of the formula:
wherein
n is 1 or 2;
m is 0, 1, 2, 4, or 5;
q is 0 or 1;
t is 0 or 1;
R2 is alkyl having from 1 to 3 carbon atoms;
R3 is hydrogen, halo, alkyl having from 1 to 3 carbon atoms, or alkoxy having from 1 to 3 carbon atoms;
A is phenyl, unsubstituted or substituted by 1 or 2 groups selected from: halo, alkyl having 1 or 2 carbon atoms, perfluoromethyl, alkoxy having 1 or 2 carbon atoms, and perfluoromethoxy; or
cycloalkyl having from 3 to 6 ring carbon atoms wherein the cycloalkyl is unsubstituted or one or two ring carbons are independently mono-substituted by methyl or ethyl; or
a 5 or 6 membered heteroaromatic ring having 1 or 2 ring heteroatoms selected from N, S and O and the heteroaromatic ring is covalently bound to the remainder of the compound of formula I by a ring carbon; and

R1 is hydrogen or alkyl having 1 or 2 carbon atoms;
or when R1 is hydrogen, a pharmaceutically acceptable salt of the compound.
15. The pharmaceutical composition of claim 14, wherein n is 1; q is 0; t is 0; R3 is hydrogen; and
A is phenyl, unsubstituted or substituted by 1 or 2 groups selected from: halo, alkyl having 1 or 2 carbon atoms, perfluoromethyl, alkoxy having 1 or 2 carbon atoms, and perfluoromethoxy.
16. The pharmaceutical composition of claim 15, wherein wherein A is 2,6-dimethylphenyl.
17. The pharmaceutical composition of claim 16, wherein the biologically active agent is selected from the group consisting of:
3-(2,6-Dimethylbenzyloxy)phenylacetic acid;
3-(2,6-Dimethylbenzyloxy)benzoic acid;
Ethyl 3-(2,6-dimethylbenzyloxy)benzoate;
6-3-(2,6-Dimethylbenzyloxy)-phenyl-hexanoic acid;
Ethyl 6-3-(2,6-dimethylbenzyloxy)-phenyl-hexanoate;
5-3-(2,6-Dimethylbenzyloxy)-phenyl-pentanoic acid;
Ethyl 5-3-(2,6-dimethylbenzyloxy)-phenyl-pentanoate;
3-3-(2,6-dimethylbenzyloxy)phenyl-propionic acid; and
Ethyl 3-3-(2,6-dimethylbenzyloxy)phenyl-propanoate.
18. The pharmaceutical composition of claim 14 in oral dosage form.
19. A biologically active agent, wherein the agent is a compound of the formula:
wherein
n is 1 or 2;
m is 0, 1, 2, 4, or 5;
q is 0 or 1;
t is 0 or 1;
R2 is alkyl having from 1 to 3 carbon atoms;
R3 is hydrogen, halo, alkyl having from 1 to 3 carbon atoms, or alkoxy having from 1 to 3 carbon atoms;
A is phenyl, unsubstituted or substituted by 1 or 2 groups selected from: halo, alkyl having 1 or 2 carbon atoms, perfluoromethyl, alkoxy having 1 or 2 carbon atoms, and perfluoromethoxy; or
cycloalkyl having from 3 to 6 ring carbon atoms wherein the cycloalkyl is unsubstituted or one or two ring carbons are independently mono-substituted by methyl or ethyl; or
a 5 or 6 membered heteroaromatic ring having 1 or 2 ring heteroatoms selected from N, S and O and the heteroaromatic ring is covalently bound to the remainder of the compound of formula I by a ring carbon; and

R1 is hydrogen or alkyl having 1 or 2 carbon atoms;
or when R1 is hydrogen, a pharmaceutically acceptable salt of the compound, wherein the agent is substantially pure.
20. The biologically active agent of claim 19, wherein n is 1; q is 0; t is 0; R3 is hydrogen; and
A is phenyl, unsubstituted or substituted by 1 or 2 groups selected from: halo, alkyl having 1 or 2 carbon atoms, perfluoromethyl, alkoxy having 1 or 2 carbon atoms, and perfluoromethoxy.
21. The biologically active agent of claim 20, wherein A is 2,6-dimethylphenyl.
22. The biologically active agent of claim 21, selected from the group consisting of:
3-(2,6-Dimethylbenzyloxy)phenylacetic acid;
3-(2,6-Dimethylbenzyloxy)benzoic acid;
Ethyl 3-(2,6-dimethylbenzyloxy)benzoate;
6-3-(2,6-Dimethylbenzyloxy)-phenyl-hexanoic acid;
Ethyl 6-3-(2,6-dimethylbenzyloxy)-phenyl-hexanoate;
5-3-(2,6-Dimethylbenzyloxy)-phenyl-pentanoic acid;
Ethyl 5-3-(2,6-dimethylbenzyloxy)-phenyl-pentanoate;
3-3-(2,6-dimethylbenzyloxy)phenyl-propionic acid; and
Ethyl 3-3-(2,6-dimethylbenzyloxy)phenyl-propanoate.
23. (canceled)
24. The method of claim 9, wherein the biologically active agent is 3-(2,6-Dimethylbenzyloxy)-phenylacetic acid.
25. The pharmaceutical composition of claim 17, wherein the biologically active agent is 3-(2,6-Dimethylbenzyloxy)-phenylacetic acid.
26. The biologically active agent of claim 22, being 3-(2,6-Dimethylbenzyloxy)-phenylacetic acid.
27. A biologically active agent, wherein the agent is a compound of the formula:
wherein
n is 1 or 2;
m is 0, 1, 2, 4, or 5;
q is 0 or 1;
t is 0 or 1;
R2 is alkyl having from 1 to 3 carbon atoms;
R3 is hydrogen, halo, alkyl having from 1 to 3 carbon atoms, or alkoxy having from 1 to 3 carbon atoms;
A is phenyl, unsubstituted or substituted by 1 or 2 groups selected from: halo, alkyl having 1 or 2 carbon atoms, perfluoromethyl, alkoxy having 1 or 2 carbon atoms, and perfluoromethoxy; or
cycloalkyl having from 3 to 6 ring carbon atoms wherein the cycloalkyl is unsubstituted or one or two ring carbons are independently mono-substituted by methyl or ethyl; or
a 5 or 6 membered heteroaromatic ring having 1 or 2 ring heteroatoms selected from N, S and O and the heteroaromatic ring is covalently bound to the remainder of the compound of formula I by a ring carbon; and

R1 is hydrogen or alkyl having 1 or 2 carbon atoms;
or when R1 is hydrogen, a pharmaceutically acceptable salt of the compound, wherein the agent is present in a mammal other than a mouse.
28. The biologically active agent of claim 27, wherein n is 1; q is 0; t is 0; R3 is hydrogen; and
A is phenyl, unsubstituted or substituted by 1 or 2 groups selected from: halo, alkyl having 1 or 2 carbon atoms, perfluoromethyl, alkoxy having 1 or 2 carbon atoms, and perfluoromethoxy.
29. The biologically active agent of claim 28, wherein A is 2,6-dimethylphenyl.
30. The biologically active agent of claim 29, selected from the group consisting of:
3-(2,6-Dimethylbenzyloxy)phenylacetic acid;
3-(2,6-Dimethylbenzyloxy)benzoic acid;
Ethyl 3-(2,6-dimethylbenzyloxy)benzoate;
6-3-(2,6-Dimethylbenzyloxy)-phenyl-hexanoic acid;
Ethyl 6-3-(2,6-dimethylbenzyloxy)-phenyl-hexanoate;
5-3-(2,6-Dimethylbenzyloxy)-phenyl-pentanoic acid;
Ethyl 5-3-(2,6-dimethylbenzyloxy)-phenyl-pentanoate;
3-3-(2,6-dimethylbenzyloxy)phenyl-propionic acid; and
Ethyl 3-3-(2,6-dimethylbenzyloxy)phenyl-propanoate.
31. The biologically active agent of claim 30, being 3-(2,6-Dimethylbenzyloxy)-phenylacetic acid.
32. The biologically active agent of claim 31, wherein the mammal is a human.
33. The biologically active agent of claim 27, wherein the mammal is a human.
34. A method for treating a mammalian subject with a condition selected from the group consisting of insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis, wherein the active agent is a compound of the formula:
wherein
n is 1 or 2;
m is 0, 1, 2, 4, or 5;
q is 0 or 1;
t is 0 or 1;
R2 is alkyl having from 1 to 3 carbon atoms;
R3 is hydrogen, halo, alkyl having from 1 to 3 carbon atoms, or alkoxy having from 1 to 3 carbon atoms;
A is phenyl, unsubstituted or substituted by 1 or 2 groups selected from: halo, alkyl having 1 or 2 carbon atoms, perfluoromethyl, alkoxy having 1 or 2 carbon atoms, and perfluoromethoxy; or
cycloalkyl having from 3 to 6 ring carbon atoms wherein the cycloalkyl is unsubstituted or one or two ring carbons are independently mono-substituted by methyl or ethyl; or
a 5 or 6 membered heteroaromatic ring having 1 or 2 ring heteroatoms selected from N, S and O and the heteroaromatic ring is covalently bound to the remainder of the compound of formula I by a ring carbon; and
R1 is hydrogen or alkyl having 1 or 2 carbon atoms;
or when R1 is hydrogen, a pharmaceutically acceptable salt of the compound.
35. The method of claim 34, wherein n is 1; q is 0; t is 0; R3 is hydrogen; and
A is phenyl, unsubstituted or substituted by 1 or 2 groups selected from: halo, alkyl having 1 or 2 carbon atoms, perfluoromethyl, alkoxy having 1 or 2 carbon atoms, and perfluoromethoxy.
36. The method of claim 35, wherein A is 2,6-dimethylphenyl.
37. The method of claim 36, wherein the active agent is selected from the group consisting of:
3-(2,6-Dimethylbenzyloxy)phenylacetic acid;
3-(2,6-Dimethylbenzyloxy)benzoic acid;
Ethyl 3-(2,6-dimethylbenzyloxy)benzoate;
6-3-(2,6-Dimethylbenzyloxy)-phenyl-hexanoic acid;
Ethyl 6-3-(2,6-dimethylbenzyloxy)-phenyl-hexanoate;
5-3-(2,6-Dimethylbenzyloxy)-phenyl-pentanoic acid;
Ethyl 5-3-(2,6-dimethylbenzyloxy)-phenyl-pentanoate;
3-3-(2,6-dimethylbenzyloxy)phenyl-propionic acid; and
Ethyl 3-3-(2,6-dimethylbenzyloxy)phenyl-propanoate.
38. The method of claim 37, wherein the active agent is 3-(2,6-Dimethylbenzyloxy)-phenylacetic acid.
39. The method of claim 34, wherein the subject is a human.
40. The method of claim 34, wherein the condition is insulin resistance syndrome or Type II Diabetes.
41. The method of claim 34, wherein the treatment reduces a symptom of diabetes or the chances of developing a symptom of diabetes, wherein the symptom is selected from the group consisting of: atherosclerosis, obesity, hypertension, hyperlipidemia, fatty liver disease, nephropathy, neuropathy, retinopathy, foot ulceration and cataracts, associated with diabetes.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

What is claimed is:

1. In a wireless transmission apparatus for constructing a wireless network by using a plurality of transmission apparatus to transmit information among it and a plurality of other communication stations, said wireless transmission apparatus being characterized by:
interface means for detecting connection bus information of a bus connected to a certain wireless transmission apparatus;
wireless information transmitting means for transmitting corresponding connection bus information to said wireless network;
wireless information receiving means for receiving connection bus information transmitted from other wireless transmission apparatus located within said wireless network; and
internal storage means for storing therein these connection bus information.
2. In a wireless transmission apparatus according to claim 1, said wireless transmission apparatus wherein said wireless information transmitting means transmits said connection bus information to said wireless network when said interface means detects the change of connection bus information.
3. In a wireless transmission apparatus for constructing a wireless network by using a plurality of transmission apparatus to transmit information among it and a plurality of other communication stations, said wireless transmission apparatus being characterized by internal storage means for storing therein connection bus information within said wireless network; and
judging means for judging based on connection bus information of said wireless network whether or not information should be transmitted by radio when it receives wireless transmission information from a connection bus connected to a corresponding wireless transmission apparatus.
4. In a wireless transmission apparatus for constructing a wireless network by using a plurality of transmission apparatus to transmit information among it and a plurality of other communication stations, said wireless transmission apparatus being characterized by:
internal storage means for storing therein connection bus information within said wireless network; and
recognizing means for recognizing a wireless transmission apparatus to which information is transmitted by radio based on connection bus information in each of said other communication stations when it receives wireless transmission information from a connection bus connected to a corresponding wireless transmission apparatus.
5. In a network management method in which a wireless network is comprised of a plurality of transmission apparatus to transmit information, said network management method being wherein network connection bus information connected to a corresponding wireless network is managed by all communication stations comprising said network.
6. In a network management method in which a wireless network is comprised of a plurality of transmission apparatus to transmit information, said network management method being wherein connection bus information of every communication station connected to a corresponding wireless network is managed by all communication stations comprising said network.
7. In a network management method in which a wireless network is comprised of a plurality of transmission apparatus to transmit information, said network management method being wherein, when connection bus information connected to its own communication station connected to a corresponding wireless network is changed, information indicative of said change of connection bus information is transmitted to the whole of said wireless network.
8. In a wireless transmission method in which a wireless network is comprised of a plurality of transmission apparatus to transmit information, said wireless transmission method being wherein, when a destination communication station to which information is transmitted by radio is designated, it is determined based on bus information of wireless transmission information in a corresponding wireless network and network connection bus information connected to a corresponding wireless network whether or not information should be transmitted by radio.
9. In a wireless transmission method in which a wireless network is comprised of a plurality of transmission apparatus to transmit information, said wireless transmission method being wherein, when a destination communication station to which information is transmitted by radio is designated, said destination communication station is designated with reference to bus information of corresponding wireless transmission information and connection bus information connected to every communication station connected to a corresponding wireless network.

1. A method for forming a substantially cylindrical window for an intracorporeal device, comprising:
placing at least partially within a mold an assembly with a longitudinal axis, said assembly comprising a proximal tubular member, a distal member, a window preform comprising a material that may soften, said window preform being disposed between said proximal tubular member and said distal member, and a mandrel disposed along said longitudinal axis at least partially within said proximal tubular member, said window preform, and said distal member;
softening said window preform; and applying force effective to urge together said proximal tubular member and said distal member effective to deform said window preform to form a window.
2. The method of claim 1, wherein said step of softening the window perform comprises heating the window preform.
3. The method of claim 1, wherein said applying force step occurs during or following said step of softening the window preform.
4. The method of claim 2, further comprising cooling the assembly.
5. The method of claim 4, further comprising removing the assembly from the mold.
6. The method of claim 5, wherein the step of removing the assembly from the mold further comprises heating.
7. The method of claim 5, further comprising removing the mandrel from the assembly.
8. The method of claim 7, wherein the step of removing the mandrel further comprises heating.
9. The method of claim 1, wherein the window preform comprises a polymeric material.
10. The method of claim 1, wherein the window preform comprises a combination of polymeric materials.
11. The method of claim 1, wherein the window preform comprises a resin that is at least partially uncured.
12. The method of claim 1, wherein the window preform comprises a combination of resins at least some of which are at least partially uncured.
13. The method of claim 1, where the window preform comprises a material selected from the group consisting of acrylic, polycarbonate, nylon, polytetrafluoroethylene (Teflon\xae), polyethylene terephthalate (PET), tensilized PET, resins, and blends thereof.
14. The method of claim 1, wherein the window preform has a length of between about 1 mm and about 11 mm.
15. The method of claim 2, wherein the step of heating the window preform is effected by at least one method selected from the group consisting of induction heating, conduction heating, infra-red radiation, ultrasonic heating, friction heating, hot air heating and allowing the temperature of the window preform to rise to ambient temperature.
16. The method of claim 15, wherein the step of heating the window perform comprises hot air heating.
17. The method of claim 16, wherein the temperature of hot air used for hot air heating is between about 300\xb0 F. and about 500\xb0 F.
18. The method of claim 1, wherein the mandrel has a distal end, and wherein said distal end is polished.
19. The method of claim 1, wherein the mold comprises a material selected from the group consisting of metal, glass, plastic, ceramic, polymer, and combinations thereof.
20. A method for forming a substantially annular window for an intracorporeal device, comprising:
placing at least partially within a translucent mold an assembly with a longitudinal axis, said assembly comprising a proximal tubular member, a distal member, a window preform comprising a material that softens when illuminated, said window preform being disposed between said proximal tubular member and said distal member, and a mandrel disposed along said longitudinal axis at least partially within said proximal tubular member, said window preform, and said distal member;
illuminating the window preform effective to soften said window preform disposed between said proximal tubular member and said distal member; and
applying force effective to urge together said proximal tubular member and said distal member effective to deform said window preform to form a window.
21. The method of claim 20, wherein said illumination comprises illumination selected from the group consisting of illumination with ultraviolet light, illumination with visible light, and illumination with infrared light.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1. A turbine combustor comprising:
an outer member coupled to a wall of the combustor, wherein there is at least one damping hole formed in the outer member; and
at least one temperature control hole formed in the wall wherein the at least one temperature control hole is formed at an angle with respect to a line perpendicular to a hot gas path in the combustor.
2. The turbine combustor of claim 1, wherein a plurality of damping holes are formed in the outer member.
3. The turbine combustor of claim 1, wherein a plurality of temperature control holes are formed in the wall, wherein the plurality of temperature control holes are formed at the angle with respect to the line perpendicular to the hot gas path.
4. The turbine combustor of claim 3, wherein the plurality of temperature control holes are each formed at an angle of about 10 to about 80 degrees with respect to the line perpendicular to the hot gas path.
5. The turbine combustor of claim 3, comprising a plurality of members formed on an inner side of the wall, wherein each member is proximate each temperature control hole, the plurality of members configured to direct a treatment fluid along the inner side of the wall.
6. The turbine combustor of claim 1, wherein the at least one temperature control hole is formed at the angle of about 10 to about 80 degrees with respect to the line perpendicular to the hot gas path, the at least one temperature control hole providing effusion temperature control for the wall.
7. The turbine combustor of claim 1, comprising at least one member formed on an inner side of the wall and proximate the at least one temperature control hole, the at least one member configured to direct a treatment fluid along the inner side of the wall.
8. The turbine combustor of claim 1, wherein the outer member coupled to the wall of the combustor forms a Hemholtz resonator tuned to a combustion dynamics frequency.
9. An apparatus for damping and controlling a temperature of a portion of a combustor, the apparatus comprising:
an outer member coupled to a wall of a combustor part, at least one damping hole formed in the outer member for damping and receiving a treatment fluid, thereby forming a resonator cavity;
at least one temperature control hole formed in the wall, wherein the temperature control hole is configured to direct the treatment fluid from the resonator cavity toward a hot gas path inside the wall of the combustor part; and
at least one member formed on an inner side of the wall and proximate the at least one temperature control hole, the at least one member configured to direct the treatment fluid along the inner side of the wall.
10. The apparatus of claim 9, wherein the at least one temperature control hole is formed at an angle with respect to a line perpendicular to a hot gas path in the combustor.
11. The apparatus of claim 9, wherein a plurality of damping holes are formed in the outer member.
12. The apparatus of claim 9, wherein a plurality of temperature control holes are formed in the wall, wherein the plurality of temperature control holes are formed at an angle with respect to a line perpendicular to a hot gas path in the combustor.
13. The apparatus of claim 12, wherein the plurality of temperature control holes are each formed at an angle of about 10 to about 80 degrees with respect to the line perpendicular to the hot gas path in the combustor.
14. The apparatus of claim 12, comprising a plurality of members formed on the inner side of the wall, wherein each member is proximate each temperature control hole, the plurality of members configured to direct a treatment fluid along the inner side of the wall.
15. The apparatus of claim 9, wherein the at least one temperature control hole is formed at an angle of about 10 to about 80 degrees with respect to a line perpendicular to a hot gas path in the combustor, the at least one temperature control hole providing effusion temperature control for the wall.
16. A method for temperature control and damping a portion of a combustor, the method comprising:
flowing a treatment fluid through at least one damping hole in an outer member coupled to a wall of the combustor, wherein the outer member forms a resonator cavity that receives the treatment fluid; and
flowing the treatment fluid from the resonator cavity through at least one temperature control hole formed in the wall, wherein the at least one temperature control hole is formed at an angle with respect to a line perpendicular to a hot gas path in the combustor.
17. The method of claim 16, wherein flowing the treatment fluid through at least one damping hole comprises flowing the treatment fluid through a plurality of damping holes in the outer member.
18. The method of claim 16, wherein flowing the treatment fluid through at least one temperature control hole comprises flowing the treatment fluid through a plurality of temperature control holes, wherein the plurality of temperature control holes are formed at the angle with respect to the line perpendicular to the hot gas path.
19. The method of claim 18, wherein flowing the treatment fluid through the plurality of damping holes comprises flowing the treatment fluid through the plurality of damping holes and proximate a plurality of members formed on an inner side of the wall, the plurality of members configured to direct the treatment fluid along the inner side of the wall.
20. The method of claim 16, wherein flowing the treatment fluid through at least one temperature control hole comprises flowing the treatment fluid through the at least one temperature control hole proximate at least one member formed on an inner side of the wall, the at least one member configured to direct the treatment fluid along the inner side of the wall.